Is Arcellx Inc (ACLX) overvalued? · rev $107.9M
Arcellx Inc (ACLX) is a biotechnology company listed on NASDAQ.
This page asks whether Arcellx Inc (ACLX) looks expensive on cached numbers — not a short thesis.
Latest reported ACLX revenue for 2024-12-31 was $107.9M. Net income was -$107.3M. Revenue was down 2.2% from 2023-12-31 to 2024-12-31. ACLX currently screens at market cap $6.73B.
ACLX currently screens at market cap $6.73B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ACLX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ACLX stock page for the full model, not this heading.
Not investment advice.